Cellectis SA logo

Cellectis SA(CLLS)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.18
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CLLS

11/13/2026: CLLS (1-star) is currently NOT-A-BUY. Pass it for now.

Cellectis SA is a clinical-stage biotechnology company that develops allogeneic cell therapies and in vivo gene editing treatments. The company's main strengths lie in its proprietary TALEN gene-editing technology and internal manufacturing capabilities. Its primary growth story centers on advancing off-the-shelf CAR-T candidates and expanding into in vivo genomic medicines for chronic diseases. Key risks include ongoing cash burn, high market competition, and clinical trial execution hurdles. The stock is best suited for growth-oriented investors willing to tolerate high volatility, with key developments centered on upcoming clinical trial data readouts and partnership updates.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveCellectis offers exposure to high-growth genetic medicine and gene-editing market trends.
Momentum investorMixed fitMomentum depends heavily on episodic clinical trial data readouts and partnership announcements.
Value investorWeak fitThe company is a pre-profit, clinical-stage biotech with ongoing operating losses.
Dividend investorWeak fitCellectis pays no dividends and retains all capital for clinical development.
Low-risk investorWeak fitHigh clinical development risks and share price volatility make it unsuitable for risk-averse portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks frequently experience sharp price swings based on trial updates.
Valuation riskMedium / highValuations are heavily tied to speculative future clinical successes rather than current earnings.
Competition risk (gene editing & cell therapy)HighRapid technological advancements by rival genomic medicine companies threaten market positioning.
Business qualityMediumThe company possesses strong proprietary science and technology platforms, but lacks commercial commercialized product sales.
Dividend incomeLow / noneNo dividend is paid or expected in the near term.
Execution riskHighSuccess relies entirely on navigating complex clinical trials, manufacturing scaling, and regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 118.86M USD
Price to earnings Ratio -
1Y Target Price 4.45
Price to earnings Ratio -
1Y Target Price 4.45
Volume (30-day avg) 95.4K shares
Beta 2.94
52 Weeks Range 0.88 - 5.45
Updated Date 11/15/2026
52 Weeks Range 0.88 - 5.45
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.64

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -29.76%
Avg. Invested days 28
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CLLS receives a 3-star rating based on the available scored pillars. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
CLLS has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and moderate ownership. In FY2025 versus FY2024, strong revenue growth (+75.8%) is partially offset by negative earnings growth (-83.9%), weak cash generation (FCF margin -58.3%), weak profitability (net margin -92.7%).

Financial Health Rating

★★★★★
CLLS's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 27.9%). Cash strength is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is CLLS's strongest growth driver at +75.8% FY2025 versus FY2024 (strong, 5 stars). By comparison, while earnings growth (-83.9%, negative) and free-cash-flow growth (-317.7%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 13.4% (soft) and 92.5% of outstanding shares are publicly tradable (strong). Insider ownership is only 0.07%, which materially reduces the ownership score.

Top 5 Institutional Investors

B Group, Inc 3.26%
Long Focus Capital Management, LLC 2.72%
UBS Asset Mgmt Americas Inc 2.63%
Delaware Management Holdings Inc 0.23%
BlackRock Inc 0.22%

Unit Economics (Per $1K Revenue)

★★★★★
CLLS generates approximately $866 of gross profit, $-453 of operating income, and $-583 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.62%

Quantitative Style Profile

★★★★★
CLLS has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Research Collaborations and LicensingUpfront licensing fees, research funding, and milestone payments from biopharmaceutical partners utilizing Cellectis's technology.Revenue can be lumpy and depends heavily on partner activity and successful development milestones.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-12
When After Market
Estimate -0.21
Actual 0.01

Profitability

Profit Margin -
Operating Margin (TTM) -384.93%

Management Effectiveness

Return on Assets (TTM) -27.75%
Return on Equity (TTM) -307.5%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 35.26M
Price to Sales(TTM) 3.7
Enterprise Value 35.26M
Price to Sales(TTM) 3.7
Enterprise Value to Revenue 0.62
Enterprise Value to EBITDA -3.9
Shares Outstanding 72.73M
Shares Floating 67.30M
Shares Outstanding 72.73M
Shares Floating 67.30M
Percent Insiders 0.07
Percent Institutions 13.44

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.